<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112381</url>
  </required_header>
  <id_info>
    <org_study_id>ET005</org_study_id>
    <nct_id>NCT04112381</nct_id>
  </id_info>
  <brief_title>Bilateral Treatment of Medication Refractory Essential Tremor</brief_title>
  <official_title>A Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy
      procedure can be performed on both sides of the brain safely and effectively to reduce
      bilateral tremor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure related adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>rate of adverse events following the Exablate secondary procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Exablate Secondary Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalamotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exablate Model 4000 Type 1.0/1.1</intervention_name>
    <description>Exablate thalamotomy of non tremor dominant side of the brain</description>
    <arm_group_label>Exablate Secondary Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women age 22 years or older

          2. Diagnosis of medication-refractory Essential Tremor

          3. Has previously underwent an Exablate index procedure in a clinical trial or in a
             commercial setting at least 9 months prior to enrolling in this trial

          4. Able to communicate sensations during the Exablate thalamotomy procedure

        Exclusion Criteria:

          1. Has experienced any non-transient neurological event or worsening following the
             Exablate index procedure

          2. Presence of unknown or MR unsafe devices anywhere in the body

          3. Non-transient hemiparesis as determined by physical examination

          4. Clinically significant abnormal speech function as determined by a speech pathologist

          5. Pregnant or breastfeeding

          6. Unstable cardiac status

          7. Behavior(s) consistent with ethanol or substance abuse

          8. History of bleeding disorder

          9. Has received anticoagulants within one month of Exablate procedure

         10. Cerebrovascular disease

         11. Intracranial tumor

         12. Active or suspected acute or chronic uncontrolled infection

         13. Has previously had deep brain stimulation or a prior stereotactic ablation of the
             basal ganglia or thalamus

         14. Implanted objects in the skull or the brain

         15. Currently in a clinical trial involving an investigational product or non-approved use
             of a drug or device or in any other type of medical research

         16. Unable to communicate with the investigator and staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Aldrich</last_name>
      <phone>410-328-5332</phone>
      <email>cladrich@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Eisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Michael</last_name>
      <phone>212-746-7373</phone>
      <email>mam4001@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sophie O'Bryan</last_name>
      <phone>212-746-1788</phone>
      <email>soo4001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Kaplitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Somers</last_name>
      <phone>215-829-6720</phone>
      <email>keren.somers@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Kerr</last_name>
      <phone>215-829-6720</phone>
      <email>kerrm@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gordon Baltuch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Patterson</last_name>
      <phone>434-243-7336</phone>
      <email>mwp5f@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>W. Jeff Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

